Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
PE Ratio 20.50
PJP's PE Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PJP: 20.50 )
Ranked among companies with meaningful PE Ratio only.
PJP' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 20.7
Current: 20.5
0
20.7
PE Ratio without NRI 20.50
PJP's PE Ratio without NRI is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PJP: 20.50 )
Ranked among companies with meaningful PE Ratio without NRI only.
PJP' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 20.7
Current: 20.5
0
20.7
PB Ratio 2.99
PJP's PB Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PJP: 2.99 )
Ranked among companies with meaningful PB Ratio only.
PJP' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.67
Current: 2.99
0
3.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.89
PJP's Dividend Yield % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PJP: 0.89 )
Ranked among companies with meaningful Dividend Yield % only.
PJP' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.94
Current: 0.89
0
0.94
5-Year Yield-on-Cost % 0.89
PJP's 5-Year Yield-on-Cost % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PJP: 0.89 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PJP' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.94
Current: 0.89
0
0.94

More Statistics

Short Percentage of Float0.00%
52-Week Range $53.72 - 68.56
Shares Outstanding (Mil)13,050,000.00
» More Articles for PJP

Headlines

Articles On GuruFocus.com
Deer Park Road Management Invests in Altisource Portfolio Solutions Mar 28 2017 
Insiders Load Up on Tiptree Mar 28 2017 
Why Public Liability Insurance Is Ignored Among Insurers Mar 28 2017 
Despite Being Overvalued, Amazon Is a Great Long-Term Pick Mar 28 2017 
TD Securities Upgrades Franco-Nevada Mar 28 2017 
Endeavour Silver Reports Initial Assessment of El Compas Mine Mar 28 2017 
Health Care Investment Trends for 2017 Mar 28 2017 
Edward Lampert Invests in Sears Holdings Mar 28 2017 
General Motors Is Not Firing on All Cylinders Mar 28 2017 
Warren Buffett on the Importance of Moats Mar 28 2017 

More From Other Websites
Bausch & Lomb Continues to be Key Growth Driver for Valeant Mar 24 2017
New Product Launches May Boost Valeant’s Dermatology Revenue Mar 23 2017
Relistor May Be Solid Growth Opportunity for Valeant in 2017 Mar 22 2017
Trump, Biogen and Amgen Hammer Healthcare ETFs Mar 20 2017
Should You Buy Pharma ETFs Now? Mar 15 2017
[$$] Drug Stocks Look Ready To Move Higher Mar 15 2017
Trump’s ‘Obamacare Lite’ presents opportunities and perils for investors Mar 09 2017
Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs Mar 08 2017
How Mylan’s Europe Segment Performed Mar 03 2017
Hit ETFs & Stocks from the Top Sector of February Mar 01 2017
Eli Lilly & Co.’s Recent Developments Feb 28 2017
Keytruda: Merck & Co.’s Immuno-Oncology Blockbuster Drug Feb 22 2017
Trending: Financials Trade Sideways as Trump Prepares Dodd-Frank Rollback Feb 09 2017
Q4 Earnings Faring Well for Pharma ETFs Feb 06 2017
Changes in Bristol-Myers Squibb’s 4Q16 Profitability Feb 01 2017
Why Eli Lilly Expects to See Revenue Growth in 4Q16 Jan 25 2017
What Lies Ahead for Pharma ETFs? Jan 19 2017
Trending: Pound Gains as Theresa May Lays out Brexit Plan Jan 19 2017
Mylan’s Profit Margins: What Made Them Change? Jan 13 2017
Understanding Mylan’s Revenues Jan 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK